Company Profile

LAURUS LABS LTD.

NSE : LAURUSLABSBSE : 540222ISIN CODE : INE947Q01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE310.6018.35 (+6.28 % )
PREV CLOSE (Rs.) 292.25
OPEN PRICE (Rs.) 293.90
BID PRICE (QTY) 310.75 (24 )
OFFER PRICE (QTY) 311.00 (20 )
VOLUME 265421
TODAY'S LOW / HIGH (Rs.)291.10 313.95
52 WK LOW / HIGH (Rs.)61.9 345
NSE312.25 19.9 (+6.81 % )
PREV CLOSE(Rs.) 292.35
OPEN PRICE (Rs.) 292.65
BID PRICE (QTY) 312.00 (571 )
OFFER PRICE (QTY) 312.20 (272 )
VOLUME 7132918
TODAY'S LOW / HIGH(Rs.) 291.00 314.00
52 WK LOW / HIGH (Rs.)59 344.9

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.03
TTM EPS (Rs.) 10.95
P/E Ratio 28.51
Book Value (Rs.) 41.36
Face Value (Rs.) 2
MCap (Rs. in Mn) 167337.64
Price/Earning (TTM) 21.59
Price/Sales (TTM) 4.59
Price/Book (MRQ) 7.55
PAT Margin (%) 9.55
ROCE (%) 14.41
Incorporation Year : 2005

Management Info :

Malempati Venugopala Rao - Chairman - Managing Director

Registered Office :

Address : Plot No.21, J N Pharma City,Parawada, ,
Vishakhapatnam,
Andhra Pradesh-531021

Phone : 0891 3061222

Website : www.lauruslabs.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS More
26Nov11-26-2020$Laurus Labs jumps on signing definitive agreements to acquire majority stake in Richcore Laurus Labs jumps on signing

Laurus Labs is currently trading at Rs. 294.90, up by 9.85 points or 3.46% from its previous closing of Rs. 285.05 on the BSE.

The scrip opened at Rs. 294.90 and has touched a high and low of Rs. 298.80 and Rs. 293.00 respectively.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 345.00 on 30-Oct-2020 and a 52 week low of Rs. 61.90 on 24-Mar-2020.

Last one week high and low of the scrip stood at Rs. 298.80 and Rs. 266.10 respectively. The current market cap of the company is Rs. 15278.54 crore.

The promoters holding in the company stood at 32.12%, while Institutions and Non-Institutions held 27.08% and 40.79% respectively.

Laurus Labs has signed definitive agreements to acquire a majority stake in Richcore Lifesciences (Richcore). Richcore, a fast-growing biotech company based in Bengaluru with its advanced R&D and manufacturing facilities, develops and manufactures biotech products critical for manufacturing biological drugs. Richcore also helps its global customers to develop and scale-up their bioprocesses by providing contract research, development, and manufacturing services.

This acquisition marks Laurus Labs’ entry into the broader biologics and biotechnology segments, providing the company access to its high growth areas, globally and in India. The company will help and drive Richcore to achieve scale and improve product offerings. With this acquisition, company adds a fourth revenue stream to its three existing divisions - API, Formulations and Synthesis.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs is currently trading at Rs. 294.90, up by 9.85 poin..
26Nov11-26-2020$Laurus Labs, JTL Infra and Cochin Shipyard to see some action today Laurus Labs, JTL Infra and C

Laurus Labs has signed definitive agreements to acquire a majority stake in Richcore Lifesciences (Richcore). Richcore, a fast-growing biotech company based in Bengaluru with its advanced R&D and manufacturing facilities, develops and manufactures biotech products critical for manufacturing biological drugs. Richcore also helps its global customers to develop and scale-up their bioprocesses by providing contract research, development, and manufacturing services.

JTL Infra has commenced commercial production at recently acquired Mandi Gobindgarh Manufacturing Facilities. Addition of these ready to use manufacturing facilities at Mandi Gobindgarh shall strengthen company’s market share in Northern Region market. The company is expecting that with these add-on Mandi Gobindgarh facilities, revenue of the Company shall be increased by approximately Rs 200 crore on annual basis.

Cochin Shipyard is building two autonomous electric vessels with zero carbon emission for a Norwegian company. The production of the vessels began with a plate-cutting ceremony organised virtually at the company. The two vessels are being built for ASKO Maritime AS, Norway. The company signed contracts for construction and supply of the two autonomous electric ferries for the Norwegian company with an option to build two more identical vessels in July 15 this year.

Union Bank of India’s board has approved raising of equity capital up to Rs 6,800 crore (including premium, if any) during 2020-21 by way of various modes such as Public lssue (i.e. Follow-on Public Offer) and/or Rights Issue and/or Private Placements, including Qualified Institutions Placement and/or Preferential Allotment to the Government of India. The Board of Directors of the bank in its meeting held on November 25, 2020, has approved the same. Extraordinary General Meeting (EGM) for taking shareholders' approval in this regard will be held on December 30, 2020.

HDFC Bank has signed memorandum of understanding (MoU) with Inventivepreneur Chamber of Commerce & Industries (ICCI) to support SMEs and Start-ups. Through this association, ICCI will engage, enroll and support various Startups /SMEs /MSMEs to facilitate inter-alia financial and other facilities to/from HDFC Bank. HDFC Bank may offer bank accounts to Startups that are supported by Inventivepreneur and recommended by Inventivepreneur.

Shriram Transport Finance Company (STFC) has raised Rs 100 crore by issuing bonds on private placement basis. The allotment committee of the company in its meeting held on November 25, 2020, has approved and allotted senior secured rated, listed principal protected market linked redeemable Nonconvertible debentures (NCD) on Private placement basis for an issue size of Rs 75 crore plus green shoe option of Rs 25 crore.

Shradha Infraprojects’ wholly owned subsidiary -- Active Infrastructure has resumed the construction work for NIT situated at Rangilal Marg, Mangaiwari Bazar, Nagpur having Land area of around 5290 Sq. Meter. The total construction area of the said project will be around 19000 Sq. Meter. 

Laurus Labs has signed definitive agreements to acquire a major..
25Nov11-25-2020$Laurus Labs signs definitive agreements to acquire majority stake in Richcore Laurus Labs signs definitive

Laurus Labs has signed definitive agreements to acquire a majority stake in Richcore Lifesciences (Richcore). Richcore, a fast-growing biotech company based in Bengaluru with its advanced R&D and manufacturing facilities, develops and manufactures biotech products critical for manufacturing biological drugs. Richcore also helps its global customers to develop and scale-up their bioprocesses by providing contract research, development, and manufacturing services.

This acquisition marks Laurus Labs’ entry into the broader biologics and biotechnology segments, providing the company access to its high growth areas, globally and in India. The company will help and drive Richcore to achieve scale and improve product offerings. With this acquisition, company adds a fourth revenue stream to its three existing divisions - API, Formulations and Synthesis.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs has signed definitive agreements to acquire a major..
23Nov11-23-2020$Laurus Labs informs about analyst meet Laurus Labs informs about an

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulations), Laurus Labs has informed about the details of Analyst/ Institutional Investor meeting to be conducted on November 19, 2020 with Ambit's Health care Conclave. Further details as enclosed. Date of the aforesaid meetings are subject to change due to exigencies on the part of Investors/ Company. No Unpublished Price Sensitive Information will be shared during the meetings.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disc..
29Oct10-29-2020$Laurus Labs informs about outcome of board meeting Laurus Labs informs about ou
Laurus Labs has informed that the Board of Directors have approved the unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Half year ended September 30, 2020 at their meeting held on October 29, 2020, which are enclosed herewith along with the Limited Review Reports issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company. The financial results are also available on the website of the Company at www.lauruslabs.com and also on the websites of BSE and National Stock Exchange of India, viz. www.bseindia.com and www.nseinda.com respectively. The Board Meeting commenced at 2.00 PM and concluded at 3.00 PM.

The above information is a part of company’s filings submitted to BSE. 

Laurus Labs has informed that the Board of Directors have appro..
Financials More
Rs. in Millions
QTR Sep 20 ANNUAL 20
Net Profit2375.92670.47
Gross Profit 3124.9 3044.82
Operating Profit 3746.55760.46
Net Sales 1127327973.35
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Procter&Gamble Healt (BSE)
 6529.70 (2.76%)
M.Cap ( in Cr)
10889.28
JB Chem & Pharma (BSE)
 990.40 (4.00%)
M.Cap ( in Cr)
7673.34
Alkem Laboratories (BSE)
 2855.00 (1.31%)
M.Cap ( in Cr)
34061.68
Neuland Laboratories (BSE)
 1031.00 (3.11%)
M.Cap ( in Cr)
1326.67
Cadila Healthcare (BSE)
 452.00 (7.02%)
M.Cap ( in Cr)
46017.23
Shareholding Pattern More
NON-INSTITUTION 40.79 %
PROMOTERS 32.12 %
MUTUAL FUNDS/UTI 3.31 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes